Published On: Tue, May 19th, 2015

$8B drug deal is big winner for Bonderman

David Bonderman

Endo International announced on Monday that it was buying Par Pharmaceutical from Bonderman’s TPG Capital for $8.1 billion.

The deal gives TPG and co-investors a profit of $6 billion — after paying off $2.3 billion of debt — giving it a return of better than seven-fold on a roughly $850 million investment just three years ago…


By Josh Kosman

Read more about: , , , , , , ,

Wordpress site Developed by Fixing WordPress Problems